Evidence map›Paper›PMID 34220553›Full record

ReviewFrontiers in physiology2021

Vascular Endothelial Senescence: Pathobiological Insights, Emerging Long Noncoding RNA Targets, Challenges and Therapeutic Opportunities.

Xinghui Sun, Mark W Feinberg

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Metabolic regulation of endothelial senescence.Frontiers in cardiovascular medicine · 2023
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Xinghui SunDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, United States.
Mark W FeinbergCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Brigham and Women's Hospital · USUniversity of Nebraska–Lincoln · US

Funding

MiR-181b, endothelial cells, and vascular inflammationR01HL115141 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2012 to 2024
$6.8M
miR-615, AKT/eNOS signaling, and angiogenesisR01HL148207 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$2.6M
LncRNA SNHG12, vascular senescence, and atherosclerosisR01HL148355 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$2.5M
Role of lncRNA Meg3 in obesity-induced endothelial senescence and insulin resistanceR01HL150536 · NHLBI · UNIVERSITY OF NEBRASKA LINCOLN · PI SUN, XINGHUI · 2020 to 2023
$2.0M
KLF10, CD4+ T cells, and transplant arteriopathyR01HL134849 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2017 to 2020
$1.7M
LncRNA MAARS, macrophage apoptosis, and atherosclerosisR01HL153356 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI FEINBERG, MARK W · 2020 to 2023
$1.7M
NHLBI NIH HHS R01 HL115141NHLBI NIH HHS R01 HL134849NHLBI NIH HHS R01 HL148207NHLBI NIH HHS R01 HL148355NHLBI NIH HHS R01 HL150536NHLBI NIH HHS R01 HL153356
6 · The paper itself

Abstract

Cellular senescence is a stable form of cell cycle arrest in response to various stressors. While it serves as an endogenous pro-resolving mechanism, detrimental effects ensue when it is dysregulated. In this review, we introduce recent advances for cellular senescence and inflammaging, the underlying mechanisms for the reduction of nicotinamide adenine dinucleotide in tissues during aging, new knowledge learned from p16 reporter mice, and the development of machine learning algorithms in cellular senescence. We focus on pathobiological insights underlying cellular senescence of the vascular endothelium, a critical interface between blood and all tissues. Common causes and hallmarks of endothelial senescence are highlighted as well as recent advances in endothelial senescence. The regulation of cellular senescence involves multiple mechanistic layers involving chromatin, DNA, RNA, and protein levels. New targets are discussed including the roles of long noncoding RNAs in regulating endothelial cellular senescence. Emerging small molecules are highlighted that have anti-aging or anti-senescence effects in age-related diseases and impact homeostatic control of the vascular endothelium. Lastly, challenges and future directions are discussed including heterogeneity of endothelial cells and endothelial senescence, senescent markers and detection of senescent endothelial cells, evolutionary differences for immune surveillance in mice and humans, and long noncoding RNAs as therapeutic targets in attenuating cellular senescence. Accumulating studies indicate that cellular senescence is reversible. A better understanding of endothelial cellular senescence through lifestyle and pharmacological interventions holds promise to foster a new frontier in the management of cardiovascular disease risk.

Indexed as

anti-senescent therapiescellular senescenceDNA damagelong noncoding RNAsSASPvascular endothelium

Identifiers

PMID34220553
PMCPMC8242592
OpenAlexW3170242825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.